Stock · ONESOURCE · Healthcare
ONESOURCE share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for ONESOURCE SPECIALTY PHARMA LIMITED, refreshed every end-of-day run. A systematic, data-only read on ONESOURCE SPECIALTY PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads ONESOURCE as two-way with a Crack Score of 60/100 as of 21 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 21 Jul 2026
Where ONESOURCE stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
100/100Fundamental axis
83/100Money flow
52/100Result pulse · Q4 FY26
40/100Technical evidence
RS slope -6.7% (3m)
RS line well below its high
relative strength falling vs NIFTY
below 50DMA
Fundamental evidence
net profit -95.32% YoY
profit down at least 20% YoY
result score 40.0/100 (weak)
YoY growth not accelerating
Red flags
above 200DMA (not a confirmed short-side trend)
profit collapse (-95.32% YoY)
Relative valuation
P/E (TTM)
n/aP/E vs sector
n/aSector percentile
n/aPEG
n/aScanner levels from the deterministic engine run of 2026-07-21, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 21 Jul 2026
Support and resistance for ONESOURCE are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the ONESOURCE chart, refreshed every end-of-day run.
The Crack Score, and how it is built60 / 100 · Constructive
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for ONESOURCE, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on ONESOURCE reads right now.
The editorial price read on ONESOURCE is mixed. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on ONESOURCE can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving ONESOURCE.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why ONESOURCE moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
ONESOURCE SPECIALTY PHARMA LIMITED's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
40 / 100Revenue
Rs 428 crNet profit
Rs 5 crEPS (quarter)
Rs 0.40| Growth | YoY | QoQ |
|---|---|---|
| Revenue | +0.5% | +47.5% |
| Net profit | -95.3% | +105.2% |
| Net margin | +1.1% | |
Distorted by a prior-year base effect.
Figures are the Q4 FY26 result for ONESOURCE SPECIALTY PHARMA LIMITED, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter7 quarters on record
ONESOURCE SPECIALTY PHARMA LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Sep 2024. These are quarterly facts, not TTM valuation inputs.
ONESOURCE official result trail
7 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 428 cr | Rs 0.40 | -95.3% | 40/100 | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 290 cr | Rs -7.74 | n/a | 32/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 376 cr | Rs 0.92 | n/a | 60/100 | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 327 cr | Rs 0.02 | n/a | n/a | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 426 cr | Rs 8.61 | n/a | n/a | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 393 cr | Rs -6.31 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 68 cr | Rs -18.82 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
ONESOURCE SPECIALTY PHARMA LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
1,422 crNet profit (TTM)
-73.8 crEBIT (TTM)
30.2 crProfit before tax (TTM)
-92.0 crNet margin (TTM)
-5.2%Finance costs (TTM)
122 crBalance sheet, as filed 2026-03-31
Total assets
8,210 crShareholder equity
5,831 crTotal borrowings
1,276 crCash and equivalents
35.7 crInventory
439 crTrade receivables
690 crThe cash engine, latest filed year
Operating cash flow
8.5 crCapex
569 crFree cash flow
-561 crInvesting flow
-495 crFinancing flow
359 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 1,422 cr | -73.8 cr | 5,831 cr | 1,276 cr | 8.5 cr |
| FY25 | 1,445 cr | 18.0 cr | 5,881 cr | 772 cr | 21.5 cr |
Every figure is parsed from ONESOURCE SPECIALTY PHARMA LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record6 earnings calls
Every ONESOURCE earnings call BazaarBaazi has indexed, latest 31 May 2026. Read management in its own words, straight from the filed transcript.
ONESOURCE SPECIALTY PHARMA LIMITED earnings calls on record
6 calls since 28 Feb 2025
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed1 disclosure
Every recent official filing from ONESOURCE SPECIALTY PHARMA LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
ONESOURCE SPECIALTY PHARMA LIMITED's most recent official filing is a Earnings dated 31 Mar 2026.
Event Heat
61 / 100Event Heat is a dated net read of ONESOURCE SPECIALTY PHARMA LIMITED's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the ONESOURCE chart. Not a substitute for a registered research note.
| Ticker | ONESOURCE |
|---|---|
| Full name | ONESOURCE SPECIALTY PHARMA LIMITED |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE013P01021 |
| Market-cap band | ~18,989 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | ONESOURCE |
Reference chartLevels in show
The daily frame the desk reads on ONESOURCE.
FAQ11 reader questions · AEO-eligible
The line on ONESOURCE, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the ONESOURCE share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on ONESOURCE. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for ONESOURCE?
The BazaarBaazi Crack Score for ONESOURCE is 60 out of 100 as of 21 Jul 2026, a constructive reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on ONESOURCE?
Strike-level option inventory for ONESOURCE is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is ONESOURCE in and which peers does BazaarBaazi track?
ONESOURCE sits in Healthcare (mid cap), indicative market cap ~18,989 cr (indicative), ISIN INE013P01021. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on ONESOURCE SPECIALTY PHARMA LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the ONESOURCE view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on ONESOURCE is mixed, published in Systematic Read on 21 Jul 2026.
Is ONESOURCE a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-21 run of the 500-name BazaarBaazi setup scanner, ONESOURCE SPECIALTY PHARMA LIMITED sits in the Scanned tier with a setup score of 77/100 (technical 100, fundamental 83). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read ONESOURCE SPECIALTY PHARMA LIMITED's earnings call transcripts?
BazaarBaazi indexes 6 ONESOURCE earnings calls going back to 2025-02-28, latest 2026-05-31. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was ONESOURCE SPECIALTY PHARMA LIMITED's Q4 FY26 net profit?
ONESOURCE SPECIALTY PHARMA LIMITED reported a net profit of Rs 5 cr for Q4 FY26 (the quarter ended 31 March 2026). That is -95.3% year on year, a move distorted by a prior-year base effect. The figure is from the company's official NSE filing.
What was ONESOURCE SPECIALTY PHARMA LIMITED's Q4 FY26 revenue?
ONESOURCE SPECIALTY PHARMA LIMITED reported revenue of Rs 428 cr for Q4 FY26. That is +0.5% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate ONESOURCE SPECIALTY PHARMA LIMITED's Q4 FY26 result?
BazaarBaazi gives ONESOURCE SPECIALTY PHARMA LIMITED's Q4 FY26 result a Result Pulse of 40 out of 100, with a verdict of Mixed. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Onesource Specialty Pharma Ltd announced recently?
The most recent official filing on record for Onesource Specialty Pharma Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside ONESOURCE, each a living view refreshed every end-of-day run.